20 Future Greek HealthTech and MedTech Leaders

Nelson Advisors
Apr 11
13 min read

The Hellenic Healthtech Renaissance: Twenty Future Leaders Redefining the Mediterranean Medtech Landscape

The Greek innovation ecosystem has entered a period of structural maturation, characterised by a transition from nascent digital adoption to the creation of globally competitive deep-tech enterprises. As of 2025, the Greek startup ecosystem is valued at approximately $4.2 billion, with Athens emerging as a significant node in the global innovation network, ranking 120th worldwide and 26th in Western Europe.

This evolution is underpinned by the "Digital Transformation Bible 2020–2025," a foundational policy framework that has prioritised the modernisation of public health services through the deployment of "digital rails," such as the national e-Prescription system and the MyHealth mobile application operated by IDIKA S.A.. Furthermore, the 2024 National AI Strategy, "A Blueprint for Greece’s AI Transformation," has established a dedicated layer for artificial intelligence in healthcare, fostering an environment where scientific excellence from institutions like the Foundation for Research and Technology-Hellas (FORTH) and the National Centre for Scientific Research "Demokritos" can be commercialised effectively.

The financial engine driving this transformation is increasingly robust. In 2025, total capital raised by Greek startups exceeded €732 million, representing a 35% increase over 2024 levels. Within this landscape, HealthTech has emerged alongside AI and SaaS as a primary vertical for investment, attracting over 143 unique investors from around the globe.The rise of growth-stage capital, exemplified by the €130 million Big Pi Growth fund, has begun to address the historical "growth gap," allowing promising Greek ventures to scale their operations internationally while maintaining significant R&D and operational bases within the country.

This report identifies twenty future leaders, startups, spin-offs and visionary researchers, who are currently defining the frontiers of Greek healthtech and medtech.

The Macroeconomic and Institutional Underpinnings of Innovation

The trajectory of the Greek medtech sector is inextricably linked to the broader macroeconomic recovery and the strategic intervention of the Hellenic Development Bank of Investments (HDBI). The Greek economy has shifted toward a model of extroversion, where innovation-driven entrepreneurship replaces traditional consumption as a growth driver. The HDBI currently manages approximately €2.1 billion across more than 30 active venture capital funds, focusing on priority sectors such as digital transformation, life sciences, and green technology.

Institutional support through clusters like the Hellenic BioCluster (HBio) and the Hellenic Digital Health Cluster (HDHC) has created a collaborative innovation moderator that connects industry partners, academia and policy makers. HBio, established in 2006, serves as an independent not-for-profit association that has successfully bridged the gap between research institutes such as CERTH and BRFAA and major pharmaceutical players like AbbVie and ELPEN. These clusters facilitate global expansion, scale-up strategies for SMEs, and navigation of complex regulatory frameworks, which are essential for Mediterranean firms seeking to penetrate the Northern European and North American markets.

Economic Indicator	2023 Performance	2025 Projection/Status
Real GDP Growth	2.5%	Stable Positive Trend
Startup Ecosystem Value	$3.1 Billion	$4.2 Billion
Total Startup Funding	~$540 Million	>€732 Million
Active VC Funds	~21 Funds	>30 Funds
Global Startup Rank (Greece)	46th	49th (Recalibration phase)

Biopharmaceutical Process Innovation: The New Digital Layer

The biopharmaceutical industry faces a persistent bottleneck in process development, the phase where a discovered molecule is transformed into a manufacturable medicine. Historically, this phase has relied on manual, "wet-lab" experimentation, which is both time-consuming and prohibitively expensive.

1. PolyModels Hub: Standardising the Digital Backbone

PolyModels Hub, founded in 2023, is perhaps the most significant recent addition to the Greek-founded biotech software landscape. Led by former GlaxoSmithKline (GSK) scientists Antonio Benedetti and Charalampos Christodoulou, alongside software engineer Antonio Yankey, the company addresses the fundamental inefficiency of biopharma manufacturing. Their flagship platform, ModelFlow, provides a unified digital layer that integrates scientific data with physics-based and AI-driven models to optimise pharmaceutical processes.

The economic implications of ModelFlow are profound. Developing a new drug typically costs $2.5 billion, with roughly 25% ($650 million) spent on process development alone. ModelFlow has demonstrated the ability to replace over 80 physical experiments with in-silico simulations, reducing experimental workloads by more than 90%. By turning 100-experiment workflows into fewer than ten while maintaining scientific rigor, PolyModels Hub enables pharmaceutical companies to save hundreds of millions of euros per drug program.

This value proposition has allowed the company to secure four of the world’s top ten pharmaceutical companies as customers within just 18 months of its founding. In late 2025, the firm raised €7.9 million ($9 million) in Series A funding led by Molten Ventures to expand its platform into the complex biologics sector.

2. JADBio: Automated Predictive Modelling for Biomedicine

Originating as a spin-off from the University of Crete and FORTH-ICS, JADBio (Just Add Data Bio) is a leader in automated machine learning (AutoML) specifically tailored for the life sciences. Under the leadership of CEO Ioannis Tsamardinos and co-founders Vincenzo Lagani and Pavlos Charonyktakis, JADBio empowers researchers to build highly accurate predictive models from complex molecular and clinical data without requiring deep programming knowledge.

The platform utilises advanced causal discovery algorithms to identify specific biomarkers that are not just correlated with, but likely cause, particular health outcomes. This capability is critical for precision medicine, where the goal is to tailor treatments to a patient's individual genetic profile.

JADBio's ability to automate feature selection and model validation boosts the productivity of data scientists and clinicians by orders of magnitude, transforming "Gnosis Data Analysis" from a university spin-off into a globally recognized predictive analytics provider.

Diagnostic Excellence and Molecular Reagents

The decentralisation of diagnostic testing is a global healthcare priority, and Greek medtech leaders are at the forefront of developing portable, rapid, and highly accurate molecular tools.

3. BIOPIX-T: The "Pebble" and Field-Ready Diagnostics

BIOPIX-T, headquartered in Heraklion and founded by a team including Dr. George Papadakis and Professor Electra Gizeli, focuses on point-of-care (PoC) molecular diagnostics. Their primary innovation, the "Pebble," is a portable device that uses quantitative colorimetric Loop-mediated Isothermal Amplification (LAMP) technology to detect infectious diseases.

Unlike traditional PCR, which requires complex thermal cycling and laboratory infrastructure, colorimetric LAMP can be performed at a constant temperature, allowing for rapid results in field settings such as physician offices, clinics, or food production facilities. BIOPIX-T has secured €1.7 million in seed funding from Metavallon VC and Eleven Ventures, positioning it as a critical infrastructure provider for the next generation of decentralised health monitoring.

4. Enzyquest: Foundational Bio-Innovation

The growth of any biotech ecosystem requires a reliable supply of molecular biology reagents. Enzyquest, founded in 2019 by Dimitris Koutsioulis, specialises in the development and manufacturing of enzymes for research and diagnostics.Based in Heraklion, the company produces high-quality reagents that are essential for DNA amplification and sequencing.

By providing a local source of high-purity enzymes, Enzyquest mitigates the supply chain vulnerabilities exposed during the COVID-19 pandemic and supports the broader Greek R&D landscape. The company has attracted seed funding from Uni.Fund and Horizon Europe and it serves as an industrial partner for academic research projects across the European Union.

5. ResQ Biotech: Addressing the Proteotoxicity Gap

ResQ Biotech, a Patras-based R&D firm founded in 2019 by Georgios Skretas and Athina Ikonomidou, focuses on therapeutic solutions for diseases caused by protein misfolding. These "proteotoxicity" conditions include Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS).

ResQ Biotech utilizes a proprietary discovery platform to identify compounds that can rescue cells from the toxic effects of protein aggregation. By integrating biological research with drug manufacturing capabilities, the company represents the high-end "deep-tech" segment of the Greek medtech scene. Their progress is supported by the "egg - enter grow go" accelerator, highlighting the role of corporate-backed incubation in nurturing high-risk, high-reward biotechs.

Immersive Training and Surgical Engineering

As surgical procedures become increasingly complex and minimally invasive, the need for standardised, objective training and precision engineering has never been greater.

6. ORamaVR: The MAGES SDK for Medical Training

ORamaVR is a Swiss-Greek deep-tech startup that has revolutionized medical training through its proprietary MAGES SDK (Software Development Kit). Founded by Professor George Papagiannakis, Professor Eleftherios Tsiridis (a world-renowned orthopaedic surgeon), and Professor Panos Trahanias, the company is a spin-off from FORTH-ICS.

The MAGES platform allows for the creation of high-fidelity virtual reality (VR) simulations for surgical procedures, addressing the limitations of the traditional "see one, do one, teach one" apprenticeship model. In early 2026, ORamaVR raised a €4.5 million seed round led by Big Pi Ventures to accelerate its mission of providing "medical XR training" globally. The company's technology utilises advanced geometric computational models and computer graphics systems to deliver simulations that are both scientifically validated and immersive.

7. Antonia Agapi Pontiki: Precision in Patient-Specific Care

Antonia Agapi Pontiki, recognized in the Forbes 30 Under 30 Europe 2024 Science & Healthcare list, is a teaching fellow at King's College London who specializes in surgical engineering. Her work focuses on the development of patient-specific surgical tools and 3D-printed anatomical models that allow surgeons to plan and practice complex procedures with unprecedented precision.

Pontiki embodies the "diaspora talent" that bridges the gap between Greek scientific education and global clinical application, often collaborating with Greek research centres to advance the state of surgical robotics and imaging.

Digital Therapeutics and Mental Health: Passive Measurement

The transition from reactive to proactive mental healthcare is being driven by the integration of wearable sensors and "Emotion AI."

8. Feel Therapeutics: Digital Precision in Mental Health

Feel Therapeutics (formerly Sentio Solutions), co-founded by George Eleftheriou and Haris Tsirmpas, has raised $30 million across ten rounds of funding, including a Series A round in June 2024. The company provides a digital precision medicine platform that leverages passive measurement and objective data for mental healthcare.

Their core offering, the Feel Program, combines a wearable biosensors, the Feel wristband, with cognitive-behavioural therapy (CBT) and telehealth services. The wristband contains sensors for skin conductance, skin temperature, and heart rate, which allow it to detect physiological shifts associated with anxiety and depression.

By identifying a panic attack or a depressive phase as it occurs, the platform can provide immediate support, potentially preventing emergency room visits and providing insurers with quantifiable data on patient progress.

9. SENSSOS: Advanced Health Sensing

Co-founded by Evangelia Athanasiou, SENSSOS is a healthtech startup focused on developing next-generation sensing technologies for health monitoring. Recognised as a top Greek healthtech startup for 2024-2025, SENSSOS aims to provide non-invasive solutions for continuous physiological tracking, filling critical data gaps in chronic disease management.

10. E-mbracelet: Wearable Wellness Solutions

Led by CEO Maro Manoli, E-mbracelet is a startup founded by five young entrepreneurs focusing on wearable wellness technology. By prioritising the user experience and the integration of health tracking into everyday fashion, E-mbracelet represents the emerging "Gen Z" segment of the Greek startup ecosystem, which emphasises accessibility and digital-first health management.

Operational Excellence and AI in Acute Care

Hospital systems face significant operational pressure, which Greek AI leaders are addressing through automation and real-time clinical intelligence.

11. Keragon: The No-Code Healthcare Automation Hub

Keragon is a HIPAA-compliant automation platform specifically built for the healthcare sector. Founded by Panos Papageorgiou, George Makkoulis, George Eracleous, and Conno Christou, the company raised a $7.5 million seed round in early 2025.

Keragon addresses the fragmentation of healthcare data by providing over 300 integrations with various Electronic Health Records (EHRs) and AI medical tools. Their no-code editor allows healthcare organisations to automate administrative tasks, patient onboarding, and billing processes, which significantly reduces the administrative burden on clinical staff and improves overall revenue capture.

12. Aisthesis Medical: AI-Driven Acute Intervention

Aisthesis Medical, under the leadership of CEO Ioannis Gkouzionis, is focused on transforming acute care through pioneering AI technology. Their solution analyses clinical data in real-time to provide early warning systems for clinicians in high-acuity settings, such as intensive care units. By predicting adverse events before they occur, Aisthesis Medical aims to improve patient safety and optimise the allocation of hospital resources.

13. Zeit Medical: Rapid Neurological Diagnosis

Orestis Vardoulis, the founder of Zeit Medical, has developed an AI-based product focused on clinical neurology. The platform enables the quick diagnosis of acute neurological events, such as strokes, which is crucial for timely medical intervention. Vardoulis, a Greek founder who has leveraged ties between Trikala and international research centres, exemplifies the cross-border nature of modern medtech innovation.

14. DeepCure: AI Biotech in Immunology

Co-founded by Thrasyvoulos Karydis, DeepCure is an AI-native biotech company focusing on inflammation and immunology. Having recently closed its Series A round, DeepCure uses advanced deep learning models to identify novel drug candidates that can modulate the immune system. The company operates as a Greek-Israeli venture, highlighting the regional synergies becoming increasingly common in the Eastern Mediterranean tech corridor.

Consumer-Centric Health Models and Wellness

The "consumerisation" of healthcare is driving the growth of subscription-based platforms and personalised wellness solutions.

15. Numan: Personalised Digital Healthcare

Numan, founded by Sokratis Papafloratos, is a digital health platform providing subscription-based healthcare and wellness services. Having raised €51.6 million in a Series B round, Numan has expanded from its initial focus on men's health to become a broader provider of personalized treatments, diagnostics, and online consultations. By combining telehealth with direct-to-consumer pharmacy services, Numan represents a new model of convenient, proactive patient management.

16. Ovom Care: AI-Enhanced Reproductive Health

Co-founded by Felicia von Reden, Ovom Care is applying machine learning to the fertility space. Recognized in the 2025 Forbes 30 Under 30 Europe Science & Healthcare list, von Reden’s work focuses on personalizing reproductive treatment plans. By using AI to more accurately identify viable eggs and tailor hormonal treatments to individual patients, Ovom Care aims to improve the success rates of IVF and other reproductive procedures, moving away from a "one-size-fits-all" approach to fertility.

17. FoodOxys: The Biologists of Metabolic Wellness

FoodOxys, a spin-off from the University of Thessaly led by Fotis Tekos, focuses on metabolic health and the assessment of oxidative stress. By providing specialized services for the food and health sectors, FoodOxys uses biochemical markers to certify the quality of nutritional products and provide personalised wellness advice. Tekos, included in the Forbes 30 Under 30 Greek list for 2025, has successfully commercialised academic research in biochemistry to address the growing global demand for "healthy aging" and "well-being".

18. Purposeful: Leveraging Data for Drug Repurposing

Purposeful, co-founded by Georgios Drakakis and Charalampos Chomenidis, uses AI and data analytics to discover new therapeutic uses for existing, off-patent drugs. This process of drug repurposing is especially critical for treating rare diseases, where the cost of de novo drug discovery is often prohibitive.

Purposeful's platform identifies alternative effects for existing medications, significantly accelerating the path to clinical application. The company raised $2 million in seed funding from Metavallon VC, underscoring the market's interest in sustainable, high-efficiency drug development.

Specialised Research and Bioprinting Frontiers

The most advanced segment of the Greek medtech landscape involves the integration of photonics, robotics, and cellular biology.

19. PhosPrint: Laser-Enabled Bioprinting

PhosPrint, a member of the Hellenic BioCluster (HBio), is an innovative enterprise active in the field of photonics and bioprinting. By utilizing laser-based technology to "print" biological materials, PhosPrint is pushing the boundaries of regenerative medicine and tissue engineering. Their work allows for the precise placement of cells and biomolecules, which is foundational for the future creation of synthetic tissues and organs.

20. YPSILON Care Tech: Digital Health Telematics

The establishment of YPSILON Care Tech as a new spin-off from the Institute of Computer Science of FORTH marks a significant step in the commercial utilization of technological solutions developed in the Computational BioMedicine Laboratory. Dedicated to transferring innovation from research to the market, YPSILON focuses on telematics, AI in healthcare, and software quality assurance. The company is staffed by experienced professionals from the Center for eHealth Applications and Services, aiming to advance the digital transformation of both the Greek and international healthcare sectors.

The Impact of AI on the Medtech Workforce and Organisational Structure

As Greek startups adopt AI-enabled models, the organizational structures within these companies are undergoing significant shifts. The "FWD Greece: Innovation Pulse 2025-2026" report notes that organisations adopting AI may see a reduction in traditional middle-management responsibilities and an expansion of the C-suite to include AI-focused roles.This technological readiness is a key factor in Greece's emergence as a promising innovation hub in Europe.

Technology Area	Core Mechanism	Causal Health Impact
Model-Based Solutions	In-silico simulation of bioprocesses	Faster access to medicines
Emotion AI Sensors	Physiological signal passive detection	Reduced mental health ER visits
Colorimetric LAMP	Isothermal DNA/RNA amplification	Portable, low-cost molecular dx
No-Code Automation	Cross-EHR data integration	Administrative efficiency/burnout reduction
Geometric VR Models	High-fidelity surgical simulation	Objective surgical competency training

The transition toward AI integration is not merely a technological challenge but an organizational one, requiring redrafted governance models and a workforce capable of adapting to redesigned processes. Greek universities continue to produce top-tier talent, which, combined with the maturing investment landscape, positions Greece to compete globally in emerging domains like Defense Tech and HealthTech.

Challenges and Barriers to International Scaling

Despite the remarkable progress, several barriers continue to pose challenges for Greek healthtech and medtech leaders seeking to scale internationally. These include:

Fragmented Regulation: Navigating different healthcare systems and regulatory frameworks within Europe and globally remains a significant hurdle for early-stage firms.
Talent Availability: While the academic talent is strong, there is a limited availability of experienced senior personnel in highly specialised technical and commercial roles.
Early-Stage Funding: While pre-seed and seed activity has recovered (accounting for 75% of deals in 2025), there is still a perceived lack of "follow-on" capital for startups in the transition between seed and Series A rounds.
EHR Fragmentation: In the clinical setting, the low rate (14%) of provider satisfaction with integrated digital health records hinders the seamless deployment of new digital health solutions.

However, the "Greek ecosystem value" continues to grow year-over-year, and the number of foreign funds participating in funding rounds is increasing, which provides a dynamic and flexible financial environment for overcoming these barriers.

Conclusion: The Trajectory Toward a Global Hub

The Greek healthtech and medtech landscape is no longer evolving linearly; it is witnessing a gradual transformation where entrepreneurship, academic research, and policy converge. The emergence of twenty leaders across biopharma, diagnostics, immersive technology, mental healthand AI-driven care demonstrates a resilient and adaptable ecosystem that is addressing both national needs and global market gaps.

The "Brain Regain" initiative and the active engagement of the Greek diaspora are providing the necessary mentorship and capital to propel these firms onto the global stage. With the continued support of institutional players like HDBI and the innovative output of research centers like FORTH and CERTH, Greece is well-positioned to become a major hub for medtech innovation in Southern Europe.

The strides made in 2024 and 2025 have laid a solid foundation for long-term growth, signalling that the "Hellenic Healthtech Renaissance" is not a temporary surge but a structural shift toward a future-forward, innovation-based economy.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech